Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-26

Study Completion Date

2012-11-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PAI-1 Expression in Non-scarring Hair Loss

NCT02548689

Androgenetic Alopecia Telogen Effluvium Alopecia Areata

TERMINATED

Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair

NCT00690664

Scalp Health

COMPLETED

Treatment of Alopecic Scars by Follicular Unit Extraction Hair Transplantation

NCT06145672

Alopecia Scar

NOT_YET_RECRUITING NA

a Retrospective Study on the Systemic Treatment of LPP and FFA

NCT06512766

Cicatricial Alopecia Lichen Planopilaris Lichen Plano-Pilaris +4 more

COMPLETED

Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis

NCT03491267

Central Centrifugal Cicatricial Alopecia (CCCA)

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Centrifugal Scarring Alopecia Lichen Planopilaris Discoid Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.

No interventions assigned to this group

II

patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.

No interventions assigned to this group

III

Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA.
* Undergone standard of care treatment for CCSA by a WFUSM Dermatologist
* Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study
* Participants ages 30 years or older with a biopsy- proven diagnosis of LP.
* Participants ages 30 years or older with a biopsy- proven diagnosis of DLE.
* Healthy participants must be ages 30 years or older.

Exclusion Criteria

* Age less than 30 years of age.
* Clinically evident bacterial or viral infection of the scalp.
* Pregnant or nursing woman of child-bearing potential.
* Participation in any other investigative research study involving study medication.
* Inability to return for the biopsy visit.

Minimum Eligible Age

30 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes